Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Fangzhou Lou *Precision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jihuan Liang *Precision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yang SunPrecision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Fengjiao ZhangPrecision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaojie CaiPrecision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0001-7297-4865
Siyu DengPrecision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhenyao XuPrecision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Aie XuDepartment of Dermatology, Hangzhou Third People's Hospital, Hangzhou, China.
Rui ChenDepartment of Plastic Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. dr.chen@shsmu.edu.cn.ORCID http://orcid.org/0009-0001-6741-1555
Honglin WangPrecision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. honglin.wang@sjtu.edu.cn.ORCID http://orcid.org/0000-0001-6302-6927
Funding
National Natural Science Foundation of China (National Science Foundation of China) 82450903Natural Science Foundation of Shanghai (Natural Science Foundation of Shanghai Municipality) 23ZR1480700Science and Technology Commission of Shanghai Municipality (Shanghai Municipal Science and Technology Commission) 2024XJQ02
6 · The paper itself
Abstract
Keloids represent a paradigm of fibroproliferative disorders marked by abnormal extracellular matrix deposition, yet the neuronal-stromal interactions driving fibroblast dysregulation remain poorly understood. Through single-cell RNA sequencing of human keloid specimens, we identify RUNX family transcription factor 2 (RUNX2)
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Catecholaminergic neurons boost fibroblast osteogenic activity in keloid. · full record | OpenQuestion